Kevin Brady, PhD

Vice President Preclinical at Cytoseek Ltd.

Kevin joined Cytoseek in November 2021, bringing with him 17 years of leadership and early phase drug discovery and development experience. He has worked in both biotech and pharma companies, and has developed new modalities and led preclinical strategies from early discovery through to end of first in human studies. He has embarked upon cross-industry regulatory responses and position papers in the field of biologics drug development. With Cytoseek he is developing the R&D strategy of our novel precision membrane engineering technology to enhance cell therapies for cancer.